Scholar Rock said Monday it raised $36 million in a Series B financing round led by Fidelity Management and Research Company. New investor Cormorant Asset Management also participated as well as existing investors Polaris Partners, Timothy Springer, ARCH Venture Partners, EcoR1 Capital and The Kraft Group.
Scholar Rock is discovering and developing a new class of biologic therapies to selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation, resulting in therapeutic effects specifically at the source of disease.
Their proprietary technology has a unique capability for highly selective targeting of growth factors which play a fundamental role in regulating cell growth and differentiation. Modulating supracellular activation is relevant to a wide range of diseases including fibrosis, diseases of musculoskeletal systems, autoimmune diseases, and cancer.
Scholar Rock has a highly experienced management team with leaders who have helped to build successful biotech companies. The company was founded by distinguished scientists, Dr. Timothy Springer and Dr. Leonard Zon, whose key discoveries in growth factor biology are enabling the company’s therapeutic approach.